Replimune Group (NASDAQ:REPL) Shares Up 5.4% – Should You Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) traded up 5.4% during mid-day trading on Thursday . The stock traded as high as $8.61 and last traded at $8.89. 60,465 shares were traded during trading, a decline of 93% from the average session volume of 926,053 shares. The stock had previously closed at $8.43.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. HC Wainwright increased their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Stock Performance

The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm’s 50-day moving average is $8.39 and its two-hundred day moving average is $11.09. The stock has a market cap of $688.39 million, a price-to-earnings ratio of -2.91 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the previous year, the business posted ($0.25) EPS. As a group, sell-side analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,952 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the completion of the sale, the insider now owns 146,933 shares in the company, valued at approximately $1,184,279.98. This represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the completion of the sale, the chief accounting officer now owns 68,284 shares of the company’s stock, valued at approximately $549,686.20. The trade was a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock worth $603,655 in the last 90 days. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares during the last quarter. Graham Capital Management L.P. increased its holdings in shares of Replimune Group by 6.1% during the 4th quarter. Graham Capital Management L.P. now owns 30,180 shares of the company’s stock worth $365,000 after buying an additional 1,731 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Replimune Group by 0.4% during the 1st quarter. Deutsche Bank AG now owns 563,701 shares of the company’s stock worth $5,496,000 after buying an additional 2,140 shares during the last quarter. MetLife Investment Management LLC increased its holdings in Replimune Group by 7.2% in the 4th quarter. MetLife Investment Management LLC now owns 37,659 shares of the company’s stock valued at $456,000 after purchasing an additional 2,525 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock valued at $151,000 after purchasing an additional 2,545 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.